FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213481544> ?p ?o ?g. }

• W3213481544 endingPage "3382" @default.
• W3213481544 startingPage "3382" @default.
• W3213481544 abstract "Abstract BACKGROUND The revised genetic risk classification established by the European Leukemia Net (ELN) in 2017 stratifies patients diagnosed with acute myeloid leukemia (AML) into 3 prognostic categories (favourable, intermediate, and adverse) based on cytogenetic and molecular characteristics.The ELN classification is widely accepted in AML patients despite the fact that validation studies were performed in participants who received exclusively first-line treatment with intensive chemotherapy. For this reason, it is not well established whether the ELN risk groups are applicable to patients on non-intensive first-line treatment. OBJECTIVES - To describe and compare baseline characteristics at diagnosis between patients with AML treated with intensive and non-intensive therapy. - To assess whether the ELN prognostic classification is applicable in these subgroups of patients. METHODS We retrospectively analysed patients with newly diagnosed AML admitted to our center between 2007 and 2020. Patients with acute promyelocytic leukemia (M3), patients younger than 18 years old and/or patients who received exclusively supportive treatment were excluded. Demographic and clinical data, disease characteristics at diagnosis and first-line treatment were collected. Cytogenetic and molecular characteristics were used to classify patients in ELN risk groups. RESULTS Of the total of patients (n=218), one hundred and fifty-six (71.6%) received intensive chemotherapy treatment, while 62 (28.4%) were treated with non-intensive strategies. Idarubicin and cytarabine based schemes regimens (IA) were administered in most patients (98.6%) who received intensive treatment while the rest received fludarabine based regimens. One patient (0.6%) was treated with danurubicin and cytarabine liposome (CPX-351). Fifty-four (87%) patients treated with non-intensive regimens received hypomethylating agents, mostly azacitidine. Five patients (8%) were treated with venetoclax in combination with a hypomethylating agent. Table 1 shows the characteristics at diagnosis in both groups of patients. Patients who received intensive chemotherapy were younger and had higher leukocyte count, LDH values and a higher percentage of blasts in peripheral blood and bone marrow with a median of 40% and 62% blasts respectively. On the other hand, patients under non-intensive treatment more frequently presented a past history of hemopathy and a higher percentage of bone marrow dysplasia. Regarding ELN stratification significant differences were found between both groups. Patients who received aggressive chemotherapy vs patients who did not, were classified in low (28% vs. 7%), intermediate (36% vs. 58%) and high risk (36% vs. 35%) respectively (Figure 1). At the end of the follow-up, 41% of the patients who had received intensive therapy were alive while only 6.5% of the patients who had received non-intensive treatment were alive. Significant differences in survival were observed between both groups (p&lt;0.01); with 1-year overall survival (OS) of 65.8% for intensive therapy group and 49.6% for non-intensive therapy group. In the intensive chemotherapy group, significant differences in survival were observed according to ELN risk stratification (p&lt;0.01), with 5-year OS of 55%, 29% and 23.9% for low, intermediate and high-risk groups respectively. For low-risk patients, median OS was not reached while it was 20 months for the intermediate risk group and 12.2 months for the high-risk group. However, in patients receiving non-intensive therapies, there were no significant differences in survival among different prognostic categories (p=0.06). In this group, 1-year OS was 25%, 57.6% and 40.7% and median OS was 2.1, 14.8 and 10.1 months for low, intermediate and high-risk groups respectively. See Figure 2. CONCLUSIONS: As validated in previous trials, ELN classification constitutes an adequate prognostic marker for patients with newly diagnosed AML treated with intensive chemotherapy. In our series, this classification does not appear to be a good predictor of survival for patients diagnosed with AML who initiated non-intensive treatments. Further validation in prospective studies are needed to better classify this growing subgroup of patients in clinical practice. Figure 1 Figure 1. Disclosures Martín-Rojas: Celgene-BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees. Font Lopez: Pfizer: Membership on an entity's Board of Directors or advisory committees; GILEAD: Membership on an entity's Board of Directors or advisory committees; CELGENE-BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kwon: Novartis, Celgene, Gilead, Pfizer: Consultancy, Honoraria." @default.
• W3213481544 created "2021-11-22" @default.
• W3213481544 creator A5000344977 @default.
• W3213481544 creator A5001787439 @default.
• W3213481544 creator A5005659445 @default.
• W3213481544 creator A5006627066 @default.
• W3213481544 creator A5009164884 @default.
• W3213481544 creator A5015111495 @default.
• W3213481544 creator A5017689172 @default.
• W3213481544 creator A5019880854 @default.
• W3213481544 creator A5034694882 @default.
• W3213481544 creator A5037322285 @default.
• W3213481544 creator A5041888795 @default.
• W3213481544 creator A5043991937 @default.
• W3213481544 creator A5052811110 @default.
• W3213481544 creator A5054200855 @default.
• W3213481544 creator A5066434198 @default.
• W3213481544 creator A5067861051 @default.
• W3213481544 creator A5076259435 @default.
• W3213481544 date "2021-11-05" @default.
• W3213481544 modified "2023-10-18" @default.
• W3213481544 title "Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification" @default.
• W3213481544 doi "https://doi.org/10.1182/blood-2021-153202" @default.
• W3213481544 hasPublicationYear "2021" @default.
• W3213481544 type Work @default.
• W3213481544 sameAs 3213481544 @default.
• W3213481544 citedByCount "1" @default.
• W3213481544 countsByYear W32134815442023 @default.
• W3213481544 crossrefType "journal-article" @default.
• W3213481544 hasAuthorship W3213481544A5000344977 @default.
• W3213481544 hasAuthorship W3213481544A5001787439 @default.
• W3213481544 hasAuthorship W3213481544A5005659445 @default.
• W3213481544 hasAuthorship W3213481544A5006627066 @default.
• W3213481544 hasAuthorship W3213481544A5009164884 @default.
• W3213481544 hasAuthorship W3213481544A5015111495 @default.
• W3213481544 hasAuthorship W3213481544A5017689172 @default.
• W3213481544 hasAuthorship W3213481544A5019880854 @default.
• W3213481544 hasAuthorship W3213481544A5034694882 @default.
• W3213481544 hasAuthorship W3213481544A5037322285 @default.
• W3213481544 hasAuthorship W3213481544A5041888795 @default.
• W3213481544 hasAuthorship W3213481544A5043991937 @default.
• W3213481544 hasAuthorship W3213481544A5052811110 @default.
• W3213481544 hasAuthorship W3213481544A5054200855 @default.
• W3213481544 hasAuthorship W3213481544A5066434198 @default.
• W3213481544 hasAuthorship W3213481544A5067861051 @default.
• W3213481544 hasAuthorship W3213481544A5076259435 @default.
• W3213481544 hasBestOaLocation W32134815441 @default.
• W3213481544 hasConcept C104317684 @default.
• W3213481544 hasConcept C126322002 @default.
• W3213481544 hasConcept C143998085 @default.
• W3213481544 hasConcept C177713679 @default.
• W3213481544 hasConcept C185592680 @default.
• W3213481544 hasConcept C2776601000 @default.
• W3213481544 hasConcept C2776694085 @default.
• W3213481544 hasConcept C2776755627 @default.
• W3213481544 hasConcept C2778041864 @default.
• W3213481544 hasConcept C2778729363 @default.
• W3213481544 hasConcept C2779117419 @default.
• W3213481544 hasConcept C2779263901 @default.
• W3213481544 hasConcept C2781121885 @default.
• W3213481544 hasConcept C2987404301 @default.
• W3213481544 hasConcept C55493867 @default.
• W3213481544 hasConcept C71924100 @default.
• W3213481544 hasConceptScore W3213481544C104317684 @default.
• W3213481544 hasConceptScore W3213481544C126322002 @default.
• W3213481544 hasConceptScore W3213481544C143998085 @default.
• W3213481544 hasConceptScore W3213481544C177713679 @default.
• W3213481544 hasConceptScore W3213481544C185592680 @default.
• W3213481544 hasConceptScore W3213481544C2776601000 @default.
• W3213481544 hasConceptScore W3213481544C2776694085 @default.
• W3213481544 hasConceptScore W3213481544C2776755627 @default.
• W3213481544 hasConceptScore W3213481544C2778041864 @default.
• W3213481544 hasConceptScore W3213481544C2778729363 @default.
• W3213481544 hasConceptScore W3213481544C2779117419 @default.
• W3213481544 hasConceptScore W3213481544C2779263901 @default.
• W3213481544 hasConceptScore W3213481544C2781121885 @default.
• W3213481544 hasConceptScore W3213481544C2987404301 @default.
• W3213481544 hasConceptScore W3213481544C55493867 @default.
• W3213481544 hasConceptScore W3213481544C71924100 @default.
• W3213481544 hasIssue "Supplement 1" @default.
• W3213481544 hasLocation W32134815441 @default.
• W3213481544 hasOpenAccess W3213481544 @default.
• W3213481544 hasPrimaryLocation W32134815441 @default.
• W3213481544 hasRelatedWork W1968865933 @default.
• W3213481544 hasRelatedWork W2002493774 @default.
• W3213481544 hasRelatedWork W2038653121 @default.
• W3213481544 hasRelatedWork W2144969304 @default.
• W3213481544 hasRelatedWork W2482959203 @default.
• W3213481544 hasRelatedWork W2577635441 @default.
• W3213481544 hasRelatedWork W2890859706 @default.
• W3213481544 hasRelatedWork W3162530256 @default.
• W3213481544 hasRelatedWork W4247120321 @default.
• W3213481544 hasRelatedWork W93525153 @default.
• W3213481544 hasVolume "138" @default.
• W3213481544 isParatext "false" @default.
• W3213481544 isRetracted "false" @default.
• W3213481544 magId "3213481544" @default.
• W3213481544 workType "article" @default.